MCID: EST001
MIFTS: 52

Estrogen-Receptor Positive Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Estrogen-Receptor Positive Breast Cancer

MalaCards integrated aliases for Estrogen-Receptor Positive Breast Cancer:

Name: Estrogen-Receptor Positive Breast Cancer 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:0060075

Summaries for Estrogen-Receptor Positive Breast Cancer

Disease Ontology : 12 A breast cancer that is characterized by the presence of estrogen receptors.

MalaCards based summary : Estrogen-Receptor Positive Breast Cancer is related to estrogen-receptor negative breast cancer and breast cancer. An important gene associated with Estrogen-Receptor Positive Breast Cancer is HSPB8 (Heat Shock Protein Family B (Small) Member 8), and among its related pathways/superpathways are Signaling by GPCR and GPCR Pathway. The drugs Exemestane and Anastrozole have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Estrogen-Receptor Positive Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Positive Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 185)
# Related Disease Score Top Affiliating Genes
1 estrogen-receptor negative breast cancer 30.4 ERBB2 ESR1 FOXA1 PGR
2 breast cancer 30.3 AKT1 CCND1 CYP19A1 EGFR ERBB2 ESR1
3 fallopian tube carcinoma 30.3 ERBB2 ESR1 PGR TP53
4 small cell cancer of the lung 29.9 AKT1 EGFR PIK3CA TP53
5 comedo carcinoma 10.3 ERBB2 ESR1
6 bartholin's gland benign neoplasm 10.3 ESR1 PGR
7 pleomorphic adenoma carcinoma 10.3 ERBB2 TP53
8 breast malignant phyllodes tumor 10.3 PGR TP53
9 vestibular gland benign neoplasm 10.3 ESR1 PGR
10 bartholin's gland adenoma 10.3 ESR1 PGR
11 scirrhous adenocarcinoma 10.3 ERBB2 PGR
12 pancreatic neuroendocrine tumor 10.3 MTOR PIK3CA
13 breast apocrine carcinoma 10.3 ERBB2 PGR
14 vulvar syringoma 10.3 ESR1 PGR
15 endometrium carcinoma in situ 10.3 PGR TP53
16 breast papillomatosis 10.3 CCND1 ERBB2
17 hypoxia 10.3
18 lung leiomyoma 10.3 ESR1 PGR
19 glassy cell carcinoma of the cervix 10.2 ERBB2 ESR1 PGR
20 breast medullary carcinoma 10.2 ERBB2 ESR1 PGR
21 vulvar benign neoplasm 10.2 ESR1 PGR
22 breast adenoid cystic carcinoma 10.2 ERBB2 ESR1 PGR
23 apocrine adenocarcinoma 10.2 ERBB2 ESR1 PGR
24 trigonitis 10.2 ESR1 PGR
25 endometrial squamous cell carcinoma 10.2 CCND1 ESR1 PGR
26 non-proliferative fibrocystic change of the breast 10.2 CCND1 ERBB2 TP53
27 vulvar leiomyoma 10.2 ESR1 PGR
28 female reproductive endometrioid cancer 10.2 ESR1 PGR TP53
29 cervical carcinosarcoma 10.2 ESR1 PGR TP53
30 glycogen-rich clear cell breast carcinoma 10.2 ESR1 PGR TP53
31 adenosarcoma 10.2 ESR1 PGR TP53
32 luteoma 10.2 CYP19A1 FGFR2
33 tubular adenocarcinoma 10.2 ERBB2 ESR1 PGR
34 uterine corpus serous adenocarcinoma 10.2 ERBB2 PIK3CA TP53
35 paronychia 10.2 EGFR MTOR
36 intracystic papillary adenoma 10.2 ERBB2 PGR
37 gastric papillary adenocarcinoma 10.2 ERBB2 TP53
38 mixed cell type cancer 10.2 ERBB2 PGR TP53
39 breast intraductal proliferative lesion 10.2 EGFR ERBB2
40 papillary adenocarcinoma 10.2 ERBB2 PGR TP53
41 ovary adenocarcinoma 10.2 ERBB2 PIK3CA TP53
42 adult hepatocellular carcinoma 10.2 PIK3CA TP53
43 dermatosis papulosa nigra 10.2 MTOR PIK3CA
44 brain ependymoma 10.2 EGFR TP53
45 breast metaplastic carcinoma 10.2 ERBB2 PGR
46 gender identity disorder 10.2 CYP19A1 ESR1 PGR
47 estrogen excess 10.2 CYP19A1 ESR1 PGR
48 bartholin's gland disease 10.2 MTOR PGR TP53
49 mammographic density 10.2 CYP19A1 ESR1 PGR
50 transitional cell carcinoma 10.2 EGFR ERBB2 TP53

Graphical network of the top 20 diseases related to Estrogen-Receptor Positive Breast Cancer:



Diseases related to Estrogen-Receptor Positive Breast Cancer

Symptoms & Phenotypes for Estrogen-Receptor Positive Breast Cancer

GenomeRNAi Phenotypes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

26 (show top 50) (show all 61)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.64 EGFR MTOR PIK3CA
2 Decreased viability GR00107-A-1 10.64 HSPB8
3 Decreased viability GR00221-A-1 10.64 AKT1 EGFR ESR1 HSPB8 MTOR PIK3CA
4 Decreased viability GR00221-A-2 10.64 AKT1 ESR1 PIK3CA
5 Decreased viability GR00221-A-3 10.64 AKT1 ERBB2
6 Decreased viability GR00221-A-4 10.64 AKT1 EGFR ESR1 HSPB8 MTOR PIK3CA
7 Decreased viability GR00301-A 10.64 HSPB8
8 Decreased viability GR00342-S-1 10.64 MTOR
9 Decreased viability GR00342-S-2 10.64 MTOR
10 Decreased viability GR00402-S-2 10.64 AKT1 EGFR ESR1 HSPB8 MTOR PIK3CA
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-1 10.32 FOXA1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.32 FOXA1 PIK3CA
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-134 10.32 CCND1
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 10.32 MTOR
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-181 10.32 CCND1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 10.32 CCND1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.32 CCND1 FOXA1 PIK3CA
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-26 10.32 RAB31
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 10.32 FOXA1
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.32 CCND1 FOXA1 MTOR PIK3CA RAB31
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 10.32 MTOR PIK3CA
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 10.32 CCND1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.21 MTOR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.21 MTOR
25 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.21 FOXA1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.21 CCND1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.21 FOXA1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-135 10.21 NCOA3
29 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.21 FOXA1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.21 NCOA3
31 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.21 CCND1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.21 PIK3CA
33 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.21 AKT1 CCND1 FOXA1 PIK3CA MTOR
34 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.21 CCND1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-166 10.21 PIK3CA
36 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.21 AKT1 CCND1 FOXA1 NCOA3 PIK3CA
37 Increased shRNA abundance (Z-score > 2) GR00366-A-189 10.21 FOXA1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.21 PIK3CA
39 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.21 CCND1
40 Increased shRNA abundance (Z-score > 2) GR00366-A-205 10.21 FOXA1
41 Increased shRNA abundance (Z-score > 2) GR00366-A-21 10.21 CCND1
42 Increased shRNA abundance (Z-score > 2) GR00366-A-210 10.21 CCND1
43 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.21 FOXA1
44 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.21 CCND1
45 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.21 CCND1
46 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.21 AKT1 FOXA1 PIK3CA MTOR
47 Increased shRNA abundance (Z-score > 2) GR00366-A-49 10.21 PIK3CA
48 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.21 AKT1
49 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.21 FOXA1
50 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.21 AKT1

MGI Mouse Phenotypes related to Estrogen-Receptor Positive Breast Cancer:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.44 AKT1 CCND1 CYP19A1 EGFR ERBB2 ESR1
2 endocrine/exocrine gland MP:0005379 10.42 AKT1 CCND1 CYP19A1 EGFR ERBB2 ESR1
3 homeostasis/metabolism MP:0005376 10.41 AKT1 CCND1 CYP19A1 EGFR ERBB2 ESR1
4 behavior/neurological MP:0005386 10.39 AKT1 CCND1 CYP19A1 ERBB2 ESR1 FGFR2
5 cardiovascular system MP:0005385 10.38 AKT1 CCND1 CYP19A1 EGFR ERBB2 ESR1
6 growth/size/body region MP:0005378 10.38 AKT1 CCND1 CYP19A1 EGFR ERBB2 ESR1
7 immune system MP:0005387 10.37 AKT1 CCND1 CYP19A1 EGFR ESR1 FGFR2
8 adipose tissue MP:0005375 10.32 AKT1 CYP19A1 EGFR ESR1 FGFR2 MTOR
9 integument MP:0010771 10.32 AKT1 CCND1 CYP19A1 EGFR ERBB2 ESR1
10 mortality/aging MP:0010768 10.32 AKT1 CCND1 EGFR ERBB2 ESR1 FGFR2
11 hematopoietic system MP:0005397 10.29 AKT1 CCND1 CYP19A1 EGFR ESR1 FGFR2
12 embryo MP:0005380 10.28 AKT1 EGFR ERBB2 ESR1 FGFR2 MTOR
13 digestive/alimentary MP:0005381 10.24 CCND1 CYP19A1 EGFR ERBB2 ESR1 FGFR2
14 muscle MP:0005369 10.23 AKT1 CYP19A1 EGFR ERBB2 ESR1 FGFR2
15 neoplasm MP:0002006 10.17 AKT1 CCND1 EGFR ERBB2 ESR1 FGFR2
16 normal MP:0002873 10.13 AKT1 CCND1 CYP19A1 EGFR EPN3 ERBB2
17 liver/biliary system MP:0005370 10.1 AKT1 CYP19A1 EGFR ESR1 FGFR2 NCOA3
18 nervous system MP:0003631 10.1 AKT1 CCND1 CYP19A1 EGFR ERBB2 ESR1
19 hearing/vestibular/ear MP:0005377 10.03 CYP19A1 EGFR EPN3 FGFR2 NCOA3 TP53
20 reproductive system MP:0005389 9.93 AKT1 CCND1 CYP19A1 EGFR ERBB2 ESR1
21 no phenotypic analysis MP:0003012 9.91 EGFR ESR1 FGFR2 MTOR PGR PIK3CA
22 renal/urinary system MP:0005367 9.86 CYP19A1 EGFR ESR1 FGFR2 MTOR NCOA3
23 respiratory system MP:0005388 9.61 AKT1 CCND1 EGFR ERBB2 ESR1 FGFR2
24 skeleton MP:0005390 9.4 AKT1 CCND1 CYP19A1 EGFR ERBB2 ESR1

Drugs & Therapeutics for Estrogen-Receptor Positive Breast Cancer

Drugs for Estrogen-Receptor Positive Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 211)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Exemestane Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 107868-30-4 60198
2
Anastrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 120511-73-1 2187
3
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
4
Tamoxifen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 10540-29-1 2733526
5
Fulvestrant Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 129453-61-8 17756771 104741
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 22916-47-8 4189
7
Everolimus Approved Phase 4,Phase 3,Phase 2 159351-69-6 6442177
8
Sirolimus Approved, Investigational Phase 4,Phase 3,Phase 2 53123-88-9 46835353 6436030 5284616
9 Aromatase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
11 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
14 Bone Density Conservation Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 Selective Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
16 Estrogen Receptor Modulators Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Estrogen Receptor Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
18 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Estrogen Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Estrogens Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
22 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Not Applicable
24 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Antifungal Agents Phase 4,Phase 3,Phase 2
26 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
27
Docetaxel Approved, Investigational Phase 3,Not Applicable 114977-28-5 148124
28
Fluorouracil Approved Phase 3 51-21-8 3385
29
Progesterone Approved, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 57-83-0 5994
30
Bevacizumab Approved, Investigational Phase 3,Phase 2,Not Applicable 216974-75-3
31
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Not Applicable 6055-19-2, 50-18-0 2907
32
Epirubicin Approved Phase 3 56420-45-2 41867
33
Estradiol Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 50-28-2 5757
34 Estradiol valerate Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 979-32-8
35
Polyestradiol phosphate Approved Phase 3,Phase 2,Phase 1,Not Applicable 28014-46-2
36
Metformin Approved Phase 3,Phase 2 657-24-9 14219 4091
37
Goserelin Approved Phase 3,Phase 2 65807-02-5 47725 5311128
38
Trastuzumab Approved, Investigational Phase 3,Phase 2 180288-69-1 9903
39
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
40
Palbociclib Approved, Investigational Phase 3,Phase 2,Phase 1 571190-30-2 11431660 5330286 5005498
41
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
42
Doxorubicin Approved, Investigational Phase 3,Phase 2 23214-92-8 31703
43
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
44
Pertuzumab Approved Phase 3 145040-37-5, 380610-27-5 2540
45
Leuprolide Approved, Investigational Phase 3 53714-56-0 657181 3911
46
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
47
Norepinephrine Approved Phase 3 51-41-2 439260
48
Triamcinolone Approved, Vet_approved Phase 3 124-94-7 31307
49
Testosterone Approved, Investigational Phase 3 58-22-0 6013
50
Testosterone undecanoate Approved, Investigational Phase 3 5949-44-0

Interventional clinical trials:

(show top 50) (show all 154)
# Name Status NCT ID Phase Drugs
1 Safety and Efficacy of RAD001 (Everolimus) in Combination With Letrozole in the Treatment of Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer Completed NCT01231659 Phase 4 Everolimus + Letrozole
2 An Open Label Study of Postmenopausal Women With Oestrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Treated With Everolimus (RAD001) With Exemestane, With Exploratory Epigenetic Marker Analysis Completed NCT01743560 Phase 4 RAD001;Exemestane
3 Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer Unknown status NCT01093235 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil
4 Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer Unknown status NCT00893061 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
5 Letrozole or Tamoxifen Citrate in Treating Older Postmenopausal Women Undergoing Surgery for Breast Cancer Completed NCT00949598 Phase 3 letrozole;tamoxifen citrate
6 Chemotherapy or Letrozole Before Surgery in Treating Postmenopausal Women With Breast Cancer That Can Be Removed By Surgery Completed NCT00963729 Phase 3 cyclophosphamide;docetaxel;epirubicin hydrochloride;fluorouracil;letrozole
7 S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy Completed NCT01385137 Phase 3
8 Goserelin in Preventing Early Menopause in Premenopausal Women Undergoing Chemotherapy for Stage I, Stage II, or Stage III Breast Cancer Completed NCT00427245 Phase 3 cyclophosphamide;goserelin acetate
9 Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer Completed NCT00288002 Phase 3 capecitabine;cyclophosphamide;docetaxel;epirubicin hydrochloride
10 Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery Recruiting NCT01953588 Phase 3 fulvestrant;anastrozole
11 Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer Recruiting NCT02947685 Phase 3 palbociclib;trastuzumab;pertuzumab;letrozole;Anastrozole;Exemestane;Fulvestrant
12 Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial Recruiting NCT03011684 Phase 3 Tamoxifen;Letrozole
13 S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Recruiting NCT01674140 Phase 3 anastrozole;everolimus;exemestane;goserelin acetate;letrozole;leuprolide acetate;tamoxifen citrate
14 Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer Active, not recruiting NCT00265759 Phase 3 anastrozole;exemestane;letrozole
15 Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Active, not recruiting NCT00310180 Phase 3 Anastrozole;Exemestane;Letrozole;Tamoxifen Citrate
16 Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Active, not recruiting NCT00066690 Phase 3 Exemestane;Tamoxifen;Triptorelin
17 Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Active, not recruiting NCT00066703 Phase 3 exemestane;tamoxifen;triptorelin
18 S1202: Duloxetine Hydrochloride for Muscle/Joint Pain in Early-Stage Breast Cancer Receiving Hormone Therapy Active, not recruiting NCT01598298 Phase 3 duloxetine hydrochloride
19 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer Active, not recruiting NCT01547741 Phase 3 Doxorubicin;Cyclophosphamide;Docetaxel;Paclitaxel
20 Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment Active, not recruiting NCT01573442 Phase 3 testosterone
21 Higher Per Daily Treatment-Dose Radiation Therapy or Standard Per Daily Treatment Radiation Therapy in Treating Patients With Early-Stage Breast Cancer That Was Removed by Surgery Active, not recruiting NCT01349322 Phase 3
22 Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer Active, not recruiting NCT01104571 Phase 3 lapatinib ditosylate
23 A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer Active, not recruiting NCT01101438 Phase 3 metformin hydrochloride
24 Genetic Testing or Clinical Assessment in Determining the Need for Chemotherapy in Women With Breast Cancer That Involves No More Than 3 Lymph Nodes Active, not recruiting NCT00433589 Phase 3 anthracycline-based;docetaxel and capecitabine
25 Study of Anastrozole, Letrozole, or Exemestane With or Without Tamoxifen in Treating Postmenopausal Women With Hormone-Responsive Breast Cancer That Has Been Completely Removed By Surgery Active, not recruiting NCT00541086 Phase 3 anastrozole;exemestane;letrozole;tamoxifen citrate
26 S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer Active, not recruiting NCT00070564 Phase 3 AC regimen;cyclophosphamide;doxorubicin hydrochloride;paclitaxel
27 A Study to Evaluate Exemestane Tablets Combined With Ovarian Function Suppression/Ablation in Treatment of Premenopausal Breast Cancer Patients With CYP2D6*10 Mutations (STEP) Enrolling by invitation NCT03137368 Phase 3 Exemestane Tablets;Tamoxifen
28 S1222 Trial (Everolimus, Anastrozole and Fulvestrant) in Post-Menopausal Stage IV Breast Cancer Suspended NCT02137837 Phase 3 Fulvestrant;Anastrozole;Everolimus;Placebo - Anastrozole;Placebo - Everolimus
29 Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer Terminated NCT00684216 Phase 2, Phase 3 capecitabine;hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
30 Placebo-controlled Trial With Vitamin D to Prevent Worsening/Relieve Aromatase Inhibitor-induced Musculoskeletal Symptoms in Breast Cancer Patients Terminated NCT01809171 Phase 2, Phase 3 Vitamin D3;Placebo
31 Metformin and Simvastatin in Addition to Fulvestrant Unknown status NCT03192293 Phase 2 Metformin/Simvastatin/Fulvestrant
32 Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer Unknown status NCT01124695 Phase 2 tamoxifen citrate
33 Anastrozole or Fulvestrant in Treating Postmenopausal Patients With Breast Cancer Unknown status NCT00871858 Phase 2 anastrozole;fulvestrant
34 Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer Unknown status NCT00687648 Phase 2 anastrozole;cyclophosphamide;exemestane;letrozole;methotrexate;prednisolone
35 Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer Unknown status NCT00931450 Phase 1, Phase 2 exemestane;sunitinib malate
36 Fulvestrant (FASLODEX™) as a Treatment in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer Completed NCT00093002 Phase 2 Fulvestrant
37 A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) Completed NCT01234857 Phase 2 ridaforolimus + dalotuzumab;exemestane;ridaforolimus;dalotuzumab
38 Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer Completed NCT00767520 Phase 2 Exemestane + Dasatinib;Exemestane + Placebo
39 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ Completed NCT00952731 Phase 2 oral placebo;afimoxifene;tamoxifen citrate;placebo gel
40 Everolimus and Letrozole as Preoperative Therapy of Primary Breast Cancer in Post-menopausal Women Completed NCT00107016 Phase 2 RAD001, Letrozole 2.5mg;Letrozole 2.5mg
41 Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ Completed NCT01439711 Phase 2 letrozole
42 AKT Inhibitor in Oestrogen Positive Breast Cancer Completed NCT02077569 Phase 2 AZD5363
43 Neoadjuvant Letrozole Plus Metformin vs Letrozole Plus Placebo for ER-positive Postmenopausal Breast Cancer Completed NCT01589367 Phase 2 Metformin;Placebo
44 Partial Double-Blind, Placebo-Controlled Study to Assess the Effect of Anastrozole on the Endometrium in Healthy Volunteers Completed NCT00467493 Phase 2 Anastrozole
45 Study to Evaluate Exemestane With and Without SNDX-275 in Treatment of Postmenopausal Women With Advanced Breast Cancer Completed NCT00676663 Phase 2 entinostat;exemestane
46 Anastrozole and ZD1839 Compared With Fulvestrant and ZD1839 in Postmenopausal Women w/ Metastatic Breast Cancer Completed NCT00057941 Phase 2 anastrozole;gefitinib;fulvestrant
47 Tipifarnib and Fulvestrant in Hormone Receptor-Positive Metastatic Breast Cancer Completed NCT00082810 Phase 2 fulvestrant;tipifarnib
48 Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery Completed NCT00407888 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel albumin-stabilized nanoparticle formulation
49 Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms Completed NCT01194440 Phase 2 letrozole;zoledronic acid
50 Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery Completed NCT00194779 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole

Search NIH Clinical Center for Estrogen-Receptor Positive Breast Cancer

Genetic Tests for Estrogen-Receptor Positive Breast Cancer

Anatomical Context for Estrogen-Receptor Positive Breast Cancer

MalaCards organs/tissues related to Estrogen-Receptor Positive Breast Cancer:

41
Breast, Bone, Lymph Node, Brain, Testes, Lung, Ovary

Publications for Estrogen-Receptor Positive Breast Cancer

Articles related to Estrogen-Receptor Positive Breast Cancer:

(show top 50) (show all 418)
# Title Authors Year
1
Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. ( 29905023 )
2018
2
Alcohol, Smoking, and Risk of Her2-Overexpressing and Triple-Negative Breast Cancer Relative to Estrogen Receptor-Positive Breast Cancer. ( 29708591 )
2018
3
Interaction between dietary acrylamide intake and genetic variants for estrogen receptor-positive breast cancer risk. ( 29445914 )
2018
4
Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer. ( 29436393 )
2018
5
Expression signature of ten genes predicts the survival of patients with estrogen receptor positive-breast cancer that were treated with tamoxifen. ( 29928444 )
2018
6
Discovery of LSZ102, a Potent, Orally Bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer. ( 29562737 )
2018
7
miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer. ( 29247596 )
2018
8
Aurora kinase A as a possible marker for endocrine resistance in early estrogen receptor positive breast cancer. ( 29202611 )
2018
9
Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. ( 29450494 )
2018
10
Omega-3 Polyunsaturated Fatty Acids Time-Dependently Reduce Cell Viability and Oncogenic MicroRNA-21 Expression in Estrogen Receptor-Positive Breast Cancer Cells (MCF-7). ( 29342901 )
2018
11
Effect of pyruvate kinase M2-regulating aerobic glycolysis on chemotherapy resistance of estrogen receptor-positive breast cancer. ( 29782350 )
2018
12
Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer. ( 29128895 )
2018
13
Autophagy promotes escape from phosphatidylinositol 3-kinase inhibition in estrogen receptor-positive breast cancer. ( 29127189 )
2018
14
A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells. ( 29733541 )
2018
15
Wnt5a-induced cell migration is associated with the aggressiveness of estrogen receptor-positive breast cancer. ( 29765514 )
2018
16
A New Class of Agents for Estrogen-Receptor-Positive Breast Cancer. ( 29439601 )
2018
17
Elevated Aromatase (CYP19A1) Expression Is Associated with a Poor Survival of Patients with Estrogen Receptor Positive Breast Cancer. ( 29363090 )
2018
18
Nogo-B receptor increases the resistance of estrogen receptor positive breast cancer to paclitaxel. ( 29373839 )
2018
19
Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients. ( 29895278 )
2018
20
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer. ( 29483206 )
2018
21
ZNF423: A New Player in Estrogen Receptor-Positive Breast Cancer. ( 29867779 )
2018
22
Mechanisms of resistance in estrogen receptor positive breast cancer: overcoming resistance to tamoxifen/aromatase inhibitors. ( 29719270 )
2018
23
Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer. ( 29626519 )
2018
24
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. ( 29352052 )
2018
25
Sulforaphane-induced metabolomic responses with epigenetic changes in estrogen receptor positive breast cancer cells. ( 30524952 )
2018
26
Overall and Estrogen Receptor-Positive Breast Cancer Incidences Are Decreased Following Bariatric Surgery. ( 30536017 )
2018
27
HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women. ( 30458882 )
2018
28
Radiation Therapy for Positive Surgical Margins in Women ≥70 Years with Stage I, Estrogen Receptor-positive Breast Cancer. ( 30194175 )
2018
29
Correction to: Observational study on the prognostic value of testosterone and adiposity in postmenopausal estrogen receptor positive breast cancer patients. ( 30200915 )
2018
30
Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells. ( 30208932 )
2018
31
microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy. ( 30214383 )
2018
32
Targeting proteasome-associated deubiquitinases as a novel strategy for the treatment of estrogen receptor-positive breast cancer. ( 30250021 )
2018
33
Comparing protein and mRNA expressions of the human epidermal growth factor receptor family in estrogen receptor-positive breast cancer. ( 30259117 )
2018
34
Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen. ( 30275856 )
2018
35
Quantitative phosphoproteomic analysis identifies novel functional pathways of tumor suppressor DLC1 in estrogen receptor positive breast cancer. ( 30278072 )
2018
36
Palbociclib enhances activin-SMAD-induced cytostasis in estrogen receptor-positive breast cancer. ( 30343527 )
2018
37
Advanced glycation end products are elevated in estrogen receptor-positive breast cancer patients, alter response to therapy, and can be targeted by lifestyle intervention. ( 30368741 )
2018
38
Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer 18F-4FMFES in Estrogen Receptor-Positive Breast Cancer Patients: An Ongoing Phase II Clinical Trial. ( 28798032 )
2018
39
18F-16α-17β-Fluoroestradiol Binding Specificity in Estrogen Receptor-Positive Breast Cancer. ( 28956736 )
2018
40
Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer. ( 28960862 )
2018
41
18F-Fluoroestradiol PET/CT Correctly Diagnosed 18F-FDG-Avid Inflammatory Lymph Nodes in a Patient With Estrogen Receptor-Positive Breast Cancer. ( 29485433 )
2018
42
Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. ( 29676944 )
2018
43
MiR-410 Acts as a Tumor Suppressor in Estrogen Receptor-Positive Breast Cancer Cells by Directly Targeting ERLIN2 via the ERS Pathway. ( 30016800 )
2018
44
Resveratrol Inhibits Key Steps of Steroid Metabolism in a Human Estrogen-Receptor Positive Breast Cancer Model: Impact on Cellular Proliferation. ( 30042681 )
2018
45
FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. ( 30046001 )
2018
46
Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer. ( 30053906 )
2018
47
Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. ( 30054636 )
2018
48
The actin cytoskeletal architecture of estrogen receptor positive breast cancer cells suppresses invasion. ( 30061623 )
2018
49
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. ( 30089255 )
2018
50
21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer. ( 30093354 )
2018

Variations for Estrogen-Receptor Positive Breast Cancer

Expression for Estrogen-Receptor Positive Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Positive Breast Cancer.

Pathways for Estrogen-Receptor Positive Breast Cancer

Pathways related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 121)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.26 AKT1 CCND1 EGFR ERBB2 ESR1 FGFR2
2
Show member pathways
13.8 AKT1 CCND1 EGFR ERBB2 ESR1 FGFR2
3
Show member pathways
13.61 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
4
Show member pathways
13.52 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
5
Show member pathways
13.49 AKT1 CCND1 EGFR ERBB2 FGFR2 MTOR
6
Show member pathways
13.44 AKT1 CCND1 EGFR ERBB2 FGFR2 PIK3CA
7
Show member pathways
13.3 AKT1 CCND1 EGFR ERBB2 MTOR STAT5B
8
Show member pathways
13.21 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
9
Show member pathways
13.14 AKT1 CCND1 EGFR MTOR PIK3CA STAT5B
10
Show member pathways
13.12 AKT1 EGFR ESR1 NCOA3 PGR PIK3CA
11
Show member pathways
13.06 AKT1 CCND1 EGFR ERBB2 FGFR2 MTOR
12
Show member pathways
12.97 AKT1 EGFR ERBB2 MTOR PIK3CA
13
Show member pathways
12.96 AKT1 CCND1 EGFR ERBB2 PIK3CA
14
Show member pathways
12.95 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
15
Show member pathways
12.89 AKT1 CCND1 EGFR ERBB2 FGFR2 MTOR
16
Show member pathways
12.87 AKT1 CCND1 PIK3CA STAT5B TP53
17
Show member pathways
12.86 AKT1 CCND1 MTOR PIK3CA STAT5B
18 12.84 AKT1 EGFR ERBB2 FGFR2 TP53
19
Show member pathways
12.81 AKT1 ERBB2 ESR1 MTOR PIK3CA TP53
20
Show member pathways
12.81 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
21
Show member pathways
12.77 AKT1 CCND1 EGFR MTOR PIK3CA STAT5B
22
Show member pathways
12.69 AKT1 EGFR ERBB2 PIK3CA STAT5B TP53
23 12.62 CCND1 EGFR ERBB2 MTOR PIK3CA TP53
24
Show member pathways
12.62 AKT1 CCND1 EGFR ERBB2 MTOR PIK3CA
25 12.62 AKT1 CCND1 EGFR ERBB2 ESR1 FGFR2
26
Show member pathways
12.57 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
27
Show member pathways
12.54 AKT1 CCND1 MTOR PIK3CA TP53
28
Show member pathways
12.54 AKT1 CCND1 ERBB2 ESR1 MTOR PIK3CA
29 12.53 AKT1 CCND1 PIK3CA STAT5B TP53
30
Show member pathways
12.53 AKT1 CCND1 EGFR ERBB2 MTOR PIK3CA
31
Show member pathways
12.51 AKT1 CCND1 EGFR MTOR PIK3CA STAT5B
32
Show member pathways
12.5 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
33
Show member pathways
12.49 AKT1 FGFR2 MTOR PIK3CA
34
Show member pathways
12.49 AKT1 CCND1 MTOR PIK3CA STAT5B TP53
35
Show member pathways
12.48 AKT1 EGFR MTOR PIK3CA
36 12.48 EGFR EPN3 FGFR2 RAB31
37
Show member pathways
12.48 EGFR ERBB2 FGFR2 MTOR PIK3CA
38
Show member pathways
12.4 AKT1 EGFR ERBB2 PIK3CA
39 12.38 AKT1 CCND1 PIK3CA TP53
40 12.38 CCND1 PIK3CA STAT5B TP53
41
Show member pathways
12.38 AKT1 CCND1 EGFR ERBB2 ESR1 NCOA3
42
Show member pathways
12.37 AKT1 CCND1 EGFR ERBB2 ESR1 FGFR2
43
Show member pathways
12.34 AKT1 MTOR STAT5B TP53
44
Show member pathways
12.31 CCND1 ESR1 NCOA3 PGR
45 12.31 AKT1 CCND1 EGFR ERBB2 ESR1 MTOR
46 12.28 AKT1 CCND1 EGFR TP53
47 12.28 AKT1 CCND1 MTOR PIK3CA TP53
48 12.28 AKT1 EGFR ERBB2 MTOR NCOA3 STAT5B
49
Show member pathways
12.26 AKT1 FGFR2 MTOR PIK3CA
50
Show member pathways
12.26 AKT1 MTOR PIK3CA TP53

GO Terms for Estrogen-Receptor Positive Breast Cancer

Cellular components related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.43 AKT1 EGFR ESR1 MTOR NCOA3 TP53
2 nucleoplasm GO:0005654 9.4 AKT1 CCND1 EPN3 ESR1 FGFR2 FOXA1
3 cytosol GO:0005829 10.1 AKT1 CCND1 ERBB2 ESR1 HSPB8 MTOR
4 cytoplasm GO:0005737 10.1 AKT1 CCND1 EGFR EPN3 ERBB2 ESR1
5 nucleus GO:0005634 10 AKT1 CCND1 EGFR EPN3 ERBB2 ESR1

Biological processes related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.97 AKT1 CCND1 PIK3CA STAT5B TP53
2 peptidyl-tyrosine phosphorylation GO:0018108 9.92 EGFR ERBB2 FGFR2 STAT5B
3 positive regulation of protein phosphorylation GO:0001934 9.92 AKT1 CCND1 EGFR ERBB2 MTOR
4 protein autophosphorylation GO:0046777 9.89 AKT1 EGFR ERBB2 FGFR2 MTOR
5 lung development GO:0030324 9.87 EGFR FGFR2 FOXA1
6 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.86 AKT1 EGFR PIK3CA
7 liver development GO:0001889 9.85 CCND1 EGFR PIK3CA
8 positive regulation of cell growth GO:0030307 9.85 AKT1 EGFR ERBB2
9 wound healing GO:0042060 9.84 EGFR ERBB2 FGFR2 MTOR
10 positive regulation of epithelial cell proliferation GO:0050679 9.83 EGFR ERBB2 FGFR2
11 epidermal growth factor receptor signaling pathway GO:0007173 9.79 AKT1 EGFR PIK3CA
12 cellular response to estradiol stimulus GO:0071392 9.78 EGFR ESR1 NCOA3
13 cellular response to growth factor stimulus GO:0071363 9.78 AKT1 EGFR ERBB2 STAT5B
14 phosphatidylinositol 3-kinase signaling GO:0014065 9.76 AKT1 ERBB2 PIK3CA
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.76 AKT1 EGFR FGFR2 MTOR
16 protein phosphorylation GO:0006468 9.76 AKT1 CCND1 EGFR ERBB2 FGFR2 HSPB8
17 ERBB2 signaling pathway GO:0038128 9.74 EGFR ERBB2 PIK3CA
18 regulation of multicellular organism growth GO:0040014 9.73 FGFR2 PIK3CA STAT5B
19 regulation of ERK1 and ERK2 cascade GO:0070372 9.72 EGFR ERBB2 FGFR2
20 phosphatidylinositol phosphorylation GO:0046854 9.72 EGFR ERBB2 ESR1 FGFR2 PIK3CA
21 cellular response to epidermal growth factor stimulus GO:0071364 9.71 AKT1 EGFR ERBB2 STAT5B
22 negative regulation of macroautophagy GO:0016242 9.69 AKT1 MTOR PIK3CA
23 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.68 ESR1 TP53
24 positive regulation of transcription by RNA polymerase III GO:0045945 9.68 ERBB2 MTOR
25 negative regulation of cell size GO:0045792 9.67 AKT1 MTOR
26 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.66 EGFR TP53
27 mitotic G1 DNA damage checkpoint GO:0031571 9.66 CCND1 TP53
28 obsolete positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.65 AKT1 EGFR
29 regulation of branching involved in prostate gland morphogenesis GO:0060687 9.65 ESR1 FGFR2
30 response to estradiol GO:0032355 9.65 CCND1 EGFR ESR1 FOXA1 STAT5B
31 regulation of glycogen biosynthetic process GO:0005979 9.64 AKT1 MTOR
32 negative regulation of ERBB signaling pathway GO:1901185 9.63 EGFR ERBB2
33 prostate epithelial cord arborization involved in prostate glandular acinus morphogenesis GO:0060527 9.63 ESR1 FGFR2
34 anoikis GO:0043276 9.61 AKT1 MTOR PIK3CA
35 prostate epithelial cord elongation GO:0060523 9.6 ESR1 FGFR2
36 positive regulation of protein kinase B signaling GO:0051897 9.43 EGFR ERBB2 ESR1 FGFR2 MTOR PIK3CA
37 response to UV-A GO:0070141 8.8 AKT1 CCND1 EGFR
38 cell differentiation GO:0030154 10.16 AKT1 EGFR ERBB2 FGFR2 FOXA1 TP53
39 phosphorylation GO:0016310 10.09 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA
40 positive regulation of cell proliferation GO:0008284 10.08 AKT1 CCND1 EGFR FGFR2 STAT5B
41 negative regulation of apoptotic process GO:0043066 10.07 AKT1 EGFR ERBB2 FGFR2 STAT5B TP53
42 positive regulation of gene expression GO:0010628 10.04 AKT1 ERBB2 MTOR NCOA3 TP53
43 positive regulation of transcription by RNA polymerase II GO:0045944 10.02 AKT1 EGFR ESR1 FGFR2 FOXA1 NCOA3

Molecular functions related to Estrogen-Receptor Positive Breast Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.97 AKT1 EGFR ERBB2 ESR1 HSPB8 MTOR
2 nucleotide binding GO:0000166 9.88 AKT1 EGFR ERBB2 FGFR2 MTOR
3 protein kinase binding GO:0019901 9.88 AKT1 CCND1 EGFR ESR1 MTOR TP53
4 kinase activity GO:0016301 9.87 AKT1 CCND1 EGFR ERBB2 FGFR2 MTOR
5 protein tyrosine kinase activity GO:0004713 9.73 EGFR ERBB2 FGFR2 STAT5B
6 enzyme binding GO:0019899 9.73 AKT1 CCND1 EGFR ESR1 PGR TP53
7 protein kinase activity GO:0004672 9.7 AKT1 CCND1 EGFR ERBB2 FGFR2 HSPB8
8 protein phosphatase binding GO:0019903 9.67 EGFR ERBB2 TP53
9 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.63 EGFR ERBB2 FGFR2
10 nitric-oxide synthase regulator activity GO:0030235 9.13 AKT1 EGFR ESR1
11 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.02 EGFR ERBB2 ESR1 FGFR2 PIK3CA
12 ATP binding GO:0005524 10.05 AKT1 EGFR ERBB2 FGFR2 MTOR PIK3CA

Sources for Estrogen-Receptor Positive Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....